Cargando…

Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia

BACKGROUND: Characterization of novel fusion genes in acute leukemia is important for gaining information about leukemia genesis. We describe the characterization of a new ETV6 fusion gene in acute myeloid leukemia (AML) FAB M0 as a result of an uncommon translocation involving chromosomes 12 and 15...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kralik, Johanna M, Kranewitter, Wolfgang, Boesmueller , Hans, Marschon, Renate, Tschurtschenthaler, Gertraud, Rumpold, Holger, Wiesinger, Kurt, Erdel, Martin, Petzer, Andreas L, Webersinke, Gerald
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063188/ https://www.ncbi.nlm.nih.gov/pubmed/21401966 http://dx.doi.org/10.1186/1746-1596-6-19

Ejemplares similares

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

Overexpression of the proneural transcription factor ASCL1 in chronic lymphocytic leukemia with a t(12;14)(q23.2;q32.3)
por: Malli, Theodora, et al.
Publicado: (2018)

An ETV6::NTRK3 fusion transcript in a core‐binding factor acute myeloid leukemia
por: Coster, Lucie, et al.
Publicado: (2023)

Case Report: Identification of a novel NTRK3-AJUBA fusion co-existing with ETV6-NTRK3 fusion in papillary thyroid carcinoma
por: Yu, Qing-Xiang, et al.
Publicado: (2023)

Successful kidney transplantation in a patient with pre‐existing chronic myeloid leukemia treated with imatinib
por: Thiem, Ursula, et al.
Publicado: (2020)

The Impact of ETV6-NTRK3 Oncogenic Gene Fusions on Molecular and Signaling Pathway Alterations
por: Kinnunen, Matias, et al.
Publicado: (2023)

Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion
por: Keddy, Clare, et al.
Publicado: (2021)

The experience of successful treatment of ETV6-NTRK3-positive infant glioblastoma with entrectinib
por: Papusha, Ludmila, et al.
Publicado: (2021)

Prediction of response to systemic treatment by kinetics of circulating tumor DNA in metastatic pancreatic cancer
por: Kirchweger, Patrick, et al.
Publicado: (2022)

Infantile Fibrosarcoma With NTRK3–ETV6 Fusion Successfully Treated With the Tropomyosin‐Related Kinase Inhibitor LOXO‐101
por: Nagasubramanian, Ramamoorthy, et al.
Publicado: (2016)

Regression of ETV6-NTRK3 Infantile Glioblastoma After First-Line Treatment With Larotrectinib
por: Alharbi, Musa, et al.
Publicado: (2020)

Data of ‘Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage’
por: Kirchweger, Patrick, et al.
Publicado: (2022)

Response prediction by mutation- or methylation-specific detection of ctDNA dynamics in pretreated metastatic colorectal cancer
por: Doleschal, Bernhard, et al.
Publicado: (2023)

Secretory carcinoma of the breast containing the ETV6-NTRK3 fusion gene in a male: case report and review of the literature
por: Arce, C, et al.
Publicado: (2005)

Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
por: Pitoia, Fabián
Publicado: (2021)

HGG-37. A case ofETV6-NTRK3 fusion driven infantile hemispheric glioma (IHG) with acquired drug resistance against first- and second-generation NTRK-inhibitors
por: Ku, Dennis T L, et al.
Publicado: (2022)

ETV6–NTRK3-positive parotid mammary analogue secretory carcinoma: a case report
por: Cobo, Juan Rodríguez, et al.
Publicado: (2021)

Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report
por: Takahashi, Akimasa, et al.
Publicado: (2018)

High-grade non-intestinal type sinonasal adenocarcinoma with ETV6::NTRK3 fusion, distinct from secretory carcinoma by immunoprofile and morphology
por: Klubíčková, Natálie, et al.
Publicado: (2023)

Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment
por: Doleschal, Bernhard, et al.
Publicado: (2023)

A Pediatric Case of High-Grade Secretory Carcinoma of the Maxillary Sinus With ETV6::NTRK3 Gene Fusion, Therapeutic Implications, and Review of the Literature
por: Cardoni, Antonello, et al.
Publicado: (2022)

Current concepts of anti-EGFR targeting in metastatic colorectal cancer
por: Doleschal, Bernhard, et al.
Publicado: (2022)

Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions
por: Brčić, Iva, et al.
Publicado: (2020)

Description of an Institutional Cohort of Myeloid Neoplasms Carrying ETV6-Locus Deletions or ETV6 Rearrangements
por: Papadopoulou, Vasiliki, et al.
Publicado: (2023)

Secretory carcinoma of major and minor salivary glands with ETV6-NTRK3 gene fusion: overcoming misdiagnosis in the era of tumour-agnostic therapy with TRK inhibitors
por: Durzyńska, Monika, et al.
Publicado: (2023)

Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion
por: Bielack, S S, et al.
Publicado: (2019)

NTRK1 Fusion in Glioblastoma Multiforme
por: Kim, Jinkuk, et al.
Publicado: (2014)

Identifying patients with NTRK fusion cancer
por: Solomon, J P, et al.
Publicado: (2019)

NTRK fusion in Japanese colorectal adenocarcinomas
por: Yamashiro, Yuya, et al.
Publicado: (2021)

A review of NTRK fusions in cancer
por: Manea, Cristina Alexandra, et al.
Publicado: (2022)

Spontaneous reshaping of vertebral fractures in an adolescent with osteogenesis imperfecta
por: Montero-Lopez, Rodrigo, et al.
Publicado: (2022)

ETV6-ACSL6 fusion gene in myeloid neoplasms: clinical spectrum, current practice, and outcomes
por: Wu, Xia, et al.
Publicado: (2020)

Acute myeloid leukemia with an MN1-ETV6 fusion in a young child with Down syndrome
por: Rosenzweig, Jaclyn, et al.
Publicado: (2022)

Complex Genomic Rearrangements Involving ETV6::ABL1 Gene Fusion in an Individual with Myeloid Neoplasm
por: Qi, Zhongxia, et al.
Publicado: (2023)

Correction: NTRK1 Fusion in Glioblastoma Multiforme
Publicado: (2014)

NTRK fusions are extremely rare in bone tumours
por: Lam, Suk Wai, et al.
Publicado: (2021)

Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report
por: Wagner, Florian, et al.
Publicado: (2021)

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
por: Konicek, Bruce W., et al.
Publicado: (2018)

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
por: Drilon, A., et al.
Publicado: (2016)

NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome
por: Zhao, Xiaonan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0g65gp6l1v32r6bf7h9vu51os5